[A case of HCC with inferior caval vein tumor thrombus and multiple pulmonary metastases that remarkably responded to combination therapy of TS-1 and interferon-alpha].
A 56-year-old male was admitted to our hospital for hepatoma with portal vein thrombus and multiple intrahepatic metastases. He underwent an extended left lobectomy and a partial resection of the liver in May 2002. After two weeks from the surgery, he received intra arterial 5-FU infusion chemotherapy combined with subcutaneous interferon-alpha injection to treat the lesions in the residual liver. Four months after the surgery, hepatic vein tumor thrombus appeared in the remnant liver and it extended to the inferior caval vein. And another 4 months later, multiple pulmonary metastases were detected with computed tomography and they grew rapidly in the view of their sizes and numbers. Because the combined therapy of 5-FU/interferon-alpha was not effective to distant metastases, we started a new regimen of oral administration of TS-1 and a subcutaneous interferon-alpha injection. After 1 treatment cool, hepatic vein thrombus was markedly reduced the size and vascularity in the CT. Multiple pulmonary metastases also decreased in their sizes and numbers. No adverse effect was seen during this treatment. It was suggested that a combination therapy of TS-1 and interferon-alpha may be one of the most effective treatment modalities against advanced HCC with distant metastasis.
Nakamura
Masato
M
Dept. of Surgery, Graduate School of Medicine, Osaka University.
Nagano
Hiroaki
H
Sakon
Masato
M
Yamamoto
Tameyoshi
T
Ota
Hideo
H
Wada
Hiroshi
H
Yoshioka
Shinichi
S
Kato
Hitoshi
H
Damdinsuren
Bazarragchaa
B
Marubashi
Shigeru
S
Miyamoto
Atsushi
A
Takeda
Yutaka
Y
Umeshita
Koji
K
Nakamori
Shoji
S
Dono
Keizo
K
Monden
Morito
M
D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D006498:Hepatectomy; D006801:Humans; D007261:Infusions, Intra-Arterial; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000473:pathology* / Q000628:therapy*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000187:drug effects / Q000473:pathology*; D010094:Oxonic Acid / Q000008:administration & dosage; D011013:Pneumonectomy; D011725:Pyridines / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D017131:Thrombectomy; D014682:Vena Cava, Inferior / Q000473:pathology*
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004338:Drug Combinations; D016898:Interferon-alpha; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid